2-chloro-3-methyl-N-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl]quinoline-4-carboxamide | 853407-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-chloro-3-methyl-N-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl]quinoline-4-carboxamide
• CAS: 853407-60-0
• 化学式: C₃₁H₃₅ClN₄O
• 分子量: 515.098
• InChiKey: VRNGRBIMQBSIJF-UHFFFAOYSA-N

物化性质

• 熔点：
  90-95 °C
• 沸点：
  725.0±60.0 °C(predicted)
• 密度：
  1.219±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-3-methyl-N-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl]quinoline-4-carboxamide 、 N-甲基哌嗪 反应 5.0h， 以80%的产率得到3-methyl-2-(4-methylpiperazin-1-yl)-N-(7-(5,6,7,8-tetrahydroacridin-9-ylamino)heptyl)quinoline-4-carboxamide
  参考文献：
  名称：

  Further Studies on the Interaction of the 5-Hydroxytryptamine₃ (5-HT₃) Receptor with Arylpiperazine Ligands. Development of a New 5-HT₃ Receptor Ligand Showing Potent Acetylcholinesterase Inhibitory Properties

  摘要：

  Novel arylpiperazine derivatives bearing lipophilic probes were designed, synthesized, and evaluated for their potential ability to interact with the 5-hydroxytryptamine(3) (5-HT3) receptor. Most of the new compounds show subnanomolar 5-HT3 receptor affinity. Ester 6bc showing a picomolar K-i value is one of the most potent 5-HT3 receptor ligands so far synthesized. The structure-affinity relationship study suggests the existence of a certain degree of conformational freedom of the amino acid residues interacting with the substituents in positions 3 and 4 of the quipazine quinoline nucleus. Thus, the tacrine-related heterobivalent ligand 6o was designed in an attempt to capitalize on the evidence of such a steric tolerance. Compound 6o shows a nanomolar potency for both the 5-HT3 receptor and the human AChE and represents the first example of a rationally designed high-affinity 5-HT3 receptor ligand showing nanomolar AChE inhibitory activity. Finally, the computational analysis performed on compound 6o allowed the rationalization of the structure-energy determinants for AChE versus BuChE selectivity and revealed the existence of a subsite at the boundary of the 5-HT3 receptor extracellular domain, which could represent a "peripheral" site similar to that evidenced in the AChE gorge.

  DOI：

  10.1021/jm0493461
• 作为产物：
  描述：

  2-羟基-3-甲基-4-喹啉羧酸 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-chloro-3-methyl-N-[7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl]quinoline-4-carboxamide
  参考文献：
  名称：

  Further Studies on the Interaction of the 5-Hydroxytryptamine₃ (5-HT₃) Receptor with Arylpiperazine Ligands. Development of a New 5-HT₃ Receptor Ligand Showing Potent Acetylcholinesterase Inhibitory Properties

  摘要：

  Novel arylpiperazine derivatives bearing lipophilic probes were designed, synthesized, and evaluated for their potential ability to interact with the 5-hydroxytryptamine(3) (5-HT3) receptor. Most of the new compounds show subnanomolar 5-HT3 receptor affinity. Ester 6bc showing a picomolar K-i value is one of the most potent 5-HT3 receptor ligands so far synthesized. The structure-affinity relationship study suggests the existence of a certain degree of conformational freedom of the amino acid residues interacting with the substituents in positions 3 and 4 of the quipazine quinoline nucleus. Thus, the tacrine-related heterobivalent ligand 6o was designed in an attempt to capitalize on the evidence of such a steric tolerance. Compound 6o shows a nanomolar potency for both the 5-HT3 receptor and the human AChE and represents the first example of a rationally designed high-affinity 5-HT3 receptor ligand showing nanomolar AChE inhibitory activity. Finally, the computational analysis performed on compound 6o allowed the rationalization of the structure-energy determinants for AChE versus BuChE selectivity and revealed the existence of a subsite at the boundary of the 5-HT3 receptor extracellular domain, which could represent a "peripheral" site similar to that evidenced in the AChE gorge.

  DOI：

  10.1021/jm0493461

文献信息

• Bivalent Ligands for the Serotonin 5-HT₃ Receptor
  作者：Andrea Cappelli、Monica Manini、Marco Paolino、Andrea Gallelli、Maurizio Anzini、Laura Mennuni、Marta Del Cadia、Francesca De Rienzo、M. Cristina Menziani、Salvatore Vomero

  DOI：10.1021/ml2000388

  日期：2011.8.11

  The serotonin 5-HT3 receptor is a ligand-gated ion channel, which by virtue of its pentameric architecture, can be considered to be an intriguing example of intrinsically multivalent biological receptors. This paper describes a general design approach to the study of multivalency in this multimeric ion channel. Bivalent ligands for 5-HT3 receptor have been designed by linking an arylpiperazine moiety to probes showing. different functional features. Both homobivalent and heterobivalent ligands have shown 5-HT3 receptor affinity in the nanomolar range, providing evidence for the viability of our design approach. Moreover, the high affinity shown by homobivalent ligands suggests that bivalency is a promising approach in 5-HT3 receptor modulation and provides the rational basis for applying the concepts of multivalency to the study of 5-HT3 receptor function.
• Further Studies on the Interaction of the 5-Hydroxytryptamine₃ (5-HT₃) Receptor with Arylpiperazine Ligands. Development of a New 5-HT₃ Receptor Ligand Showing Potent Acetylcholinesterase Inhibitory Properties
  作者：Andrea Cappelli、Andrea Gallelli、Monica Manini、Maurizio Anzini、Laura Mennuni、Francesco Makovec、M. Cristina Menziani、Stefano Alcaro、Francesco Ortuso、Salvatore Vomero

  DOI：10.1021/jm0493461

  日期：2005.5.1

  Novel arylpiperazine derivatives bearing lipophilic probes were designed, synthesized, and evaluated for their potential ability to interact with the 5-hydroxytryptamine(3) (5-HT3) receptor. Most of the new compounds show subnanomolar 5-HT3 receptor affinity. Ester 6bc showing a picomolar K-i value is one of the most potent 5-HT3 receptor ligands so far synthesized. The structure-affinity relationship study suggests the existence of a certain degree of conformational freedom of the amino acid residues interacting with the substituents in positions 3 and 4 of the quipazine quinoline nucleus. Thus, the tacrine-related heterobivalent ligand 6o was designed in an attempt to capitalize on the evidence of such a steric tolerance. Compound 6o shows a nanomolar potency for both the 5-HT3 receptor and the human AChE and represents the first example of a rationally designed high-affinity 5-HT3 receptor ligand showing nanomolar AChE inhibitory activity. Finally, the computational analysis performed on compound 6o allowed the rationalization of the structure-energy determinants for AChE versus BuChE selectivity and revealed the existence of a subsite at the boundary of the 5-HT3 receptor extracellular domain, which could represent a "peripheral" site similar to that evidenced in the AChE gorge.